### Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form 4

#### BIODELIVERY SCIENCES INTERNATIONAL INC

Form 4

September 12, 2007

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:

3235-0287

Check this box if no longer subject to

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

January 31, Expires: 2005

**OMB APPROVAL** 

Section 16. Form 4 or Form 5

Estimated average burden hours per response... 0.5

obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* HOPKINS CAPITAL GROUP II LLC

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to Issuer

**BIODELIVERY SCIENCES** INTERNATIONAL INC [BDSI]

(Check all applicable)

(Last)

(First) (Middle) 3. Date of Earliest Transaction

Director X\_\_ 10% Owner \_X\_ Other (specify Officer (give title

709 THE HAMPTONS LN.

(Month/Day/Year) 09/05/2007

below) below) \*(see below)

6. Individual or Joint/Group Filing(Check

Applicable Line)

(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

Person

**TOWN AND** COUNTRY, MO 63017

> (City) (State)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)

(Month/Day/Year) Execution Date, if

2. Transaction Date 2A. Deemed

(Month/Day/Year)

(Zip)

3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following

6. Ownership 7. Nature of Form: Direct Indirect (D) or Beneficial Indirect (I) Ownership (Instr. 4) (Instr. 4)

(A) or

Reported Transaction(s) (Instr. 3 and 4)

3,696,523

Code V Amount (D) Price

 $D^{(1)}$ 

Common Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

### Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	\$ 5.55	09/05/2007		J(2)	475,000	09/05/2007	(2)	Common Stock	475,000

# **Reporting Owners**

Reporting Owner Name / Address	Relationships					
· · · · · · · · · · · · · · · · · · ·	Director	10% Owner	Officer	Other		
HOPKINS CAPITAL GROUP II LLC						
709 THE HAMPTONS LN.		X		*(see below)		
TOWN AND COUNTRY, MO 63017						

# **Signatures**

/s/ Francis E. O'Donnell, Jr.,
Manager

09/12/2007

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reporting person directly owns the shares that are the subject of this Form 4.
- The expiration date is the close of business on the date which is second anniversary following the approval by the relevant governmental authority(ies) required for the initial launch, marketing and sale of a BEMA formulated product of the Issuer for human therapeutic use.
- (3) The warrants acquired herein were acquired as consideration for the termination of a certain option to enter into a royalty purchase agreement granted to reporting person by the Issuer pursuant to promissory note in March 2007.

#### **Remarks:**

\* In addition to being a 10% or greater owner of the Issuer, the reporting person is controlled by Francis O'Donnell Jr., who is Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2